StockNews.AI

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue

StockNews.AI • 2 hours

NUMDPTNXSAGE
High Materiality9/10

Information

Total preliminary 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, re...

Original source

AI Summary

AXSM reported Q4 2025 revenue at $196 million, 65% growth year-over-year. AUVELITY sales projected at $155.1 million for Q4 2025, showing strong demand. SUNOSI and SYMBRAVO also demonstrate significant revenue growth for 2025. Preliminary financial results subject to change pending final audit verification. AXSM continues to innovate in CNS treatments, expanding its product portfolio.

Sentiment Rationale

The impressive revenue figures indicate strong market acceptance. Historical precedents show similar growth periods lead to stock price increases.

Trading Thesis

Immediate impact from revenue announcements often leads to short-term stock volatility, unlike long-term growth prospects shown in stability.

Market-Moving

  • AXSM reported Q4 2025 revenue at $196 million, 65% growth year-over-year.
  • AUVELITY sales projected at $155.1 million for Q4 2025, showing strong demand.
  • SUNOSI and SYMBRAVO also demonstrate significant revenue growth for 2025.

Key Facts

  • AXSM reported Q4 2025 revenue at $196 million, 65% growth year-over-year.
  • AUVELITY sales projected at $155.1 million for Q4 2025, showing strong demand.
  • SUNOSI and SYMBRAVO also demonstrate significant revenue growth for 2025.
  • Preliminary financial results subject to change pending final audit verification.
  • AXSM continues to innovate in CNS treatments, expanding its product portfolio.

Companies Mentioned

  • NUMD (NUMD)
  • PTNX (PTNX)
  • SAGE (SAGE)

Corporate Developments

The revenue figures suggest robust business performance, likely influencing investor sentiment and stock price.

Axsome Therapeutics Reports Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue

New York, January 12, 2026 (GLOBE NEWSWIRE) – Axsome Therapeutics, Inc. (NASDAQ: AXSM), a pioneering biopharmaceutical company focused on central nervous system (CNS) disorders, has announced its preliminary net product revenues for the fourth quarter and full year of 2025.

Key Financial Highlights

Axsome Therapeutics reported an impressive total preliminary net product revenue of $196.0 million for the fourth quarter of 2025, reflecting a 65% increase compared to the same period last year. For the full year 2025, the company anticipates a net product revenue of approximately $638.5 million, marking a 66% growth year-over-year.

  • Preliminary fourth quarter net product sales for AUVELITY®: $155.1 million
  • Full year net product sales for AUVELITY: $507.1 million
  • Preliminary fourth quarter net product revenue for SUNOSI®: $36.7 million
  • Full year net product revenue for SUNOSI: $124.8 million
  • Preliminary fourth quarter net product sales for SYMBRAVO®: $4.1 million
  • Full year net product sales for SYMBRAVO: $6.6 million

Growth Insights and Future Prospects

The figures represent Axsome's continuous growth trajectory in the CNS pharmaceutical sector, driven primarily by its flagship products, AUVELITY, SUNOSI, and SYMBRAVO. Notably, SYMBRAVO launched commercially in June 2025, contributing to the increase in net sales.

Axsome's estimates presented here are based on preliminary unaudited information and may change upon the final financial close. The final financial results will be released once the company completes its financial closing procedures.

About Axsome Therapeutics

Axsome Therapeutics is at the forefront of developing innovative treatments for CNS conditions. The company focuses on identifying unmet medical needs and creating differentiated products that offer novel mechanisms of action. Its portfolio includes FDA-approved treatments for major depressive disorder, narcolepsy, obstructive sleep apnea, and migraine, along with several late-stage development programs aimed at addressing various neurological and psychiatric disorders affecting over 150 million Americans.

For further information, please visit www.axsome.com and follow us on LinkedIn and X.

Forward-Looking Statements

Axsome Therapeutics' announcements contain forward-looking statements regarding the company’s expectations, estimates, and projections about future events. These statements are subject to various risks and uncertainties, including but not limited to the commercial performance of SUNOSI, AUVELITY, and SYMBRAVO products, regulatory approvals, and market conditions.

For any inquiries, please contact:

  • Investors: Ashley Dong, Director, Investor Relations, (929) 687-1614, adong@axsome.com
  • Media: Darren Opland, Senior Director, Corporate Communications, (929) 837-1065, dopland@axsome.com

Related News